Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 76 Neoplasms 29 Thyroid Neoplasms 11 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Carcinoma, Anaplastic 9 Glioma 9 Brain Neoplasms 9 Multiple Myeloma 7 Colorectal Neoplasms 7 Skin Neoplasms 6 Hematologic Neoplasms 6 Thyroid Cancer, Papillary 4 Ameloblastoma 4 Lung Neoplasms 3 Histiocytosis, Langerhans-Cell 3 Glioblastoma 3 Astrocytoma 3 Rectal Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Oligodendroglioma 2 Neurofibroma, Plexiform 2 Neurocytoma 2 Neuroblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Ganglioneuroma 2

Interventions

Cyclophosphamide 155 Dexamethasone 141 Rituximab 85 fludarabine 80 Lenalidomide 72 Cytarabine 70 Bortezomib 65 fludarabine phosphate 63 Gemcitabine 62 venetoclax 55 pomalidomide 53 Etoposide 53 pembrolizumab 52 Paclitaxel 48 Cisplatin 48 Carboplatin 48 Peripheral Blood Stem Cell Transplantation 47 Filgrastim 40 Radiotherapy 39 Busulfan 37 Calcium Dobesilate 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 30 Vincristine 29 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × dabrafenib × Clear all

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡